Wells Fargo analyst Mohit Bansal maintained a Buy rating on Neurocrine (NBIX – Research Report) yesterday and set a price target of $180.00.

Corient Private Wealth LLC grew its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 64.0% during the fourth quarter, according to the company in its most recent 13F filing with ...

Envestnet Portfolio Solutions Inc. boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Neurocrine Biosciences wasn’t one of them. The 10 stocks that made the ...

Hiring Dalia Rayes as head of commercial for the global efzofitimod franchise slots another piece of the puzzle into place.

Return on Assets (ROA): Neurocrine Biosciences's financial strength is reflected in its exceptional ROA, which exceeds ...

Highlights,A substantial portion of Neurocrine Biosciences' shares is currently held by institutional entities.,Avantax ...

Even with significant expansion in the global market for antibodies used in clinical care and research, scientists recognize that there is still untapped potential for finding new antibodies. Many ...

Following big announcements from Lilly and Merck, J&J is pledging $55 billion over the next four years to open new plants.

A panel of CDC advisers, who had been set to meet in February, will discuss the current measles outbreak as well as ...

US neuroscience-focused biopharma Neurocrine Biosciences (Nasdaq: NBIX) today presented new data from the long-term, ...

Neurocrine (NBIX) presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia among the ...